Emergence of plasmid mediated AmpC β-lactamasas: Origin, importance, detection and therapeutical options;Emergencia de β-lactamasas AmpC plasmídicas (Pampc ó cefamicinasas): Origen, importancia, detección y alternatives terapéuticas

Revista Espanola de Quimioterapia

Volumn 25, Issue 2, 2012, Pages 89-99

  Seral, Cristina ^a,b   Jose Gude M ^a   Javier Castillo, F ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

AmpC gene; Bibliograf a; Cephalosporinases; CMY 2; PAmpC; Plasmidic mediated AmpC lactamases

Indexed keywords

7 ALPHA METHOXYCEPHALOSPORIN; BETA LACTAMASE AMPC; CARBAPENEM; CEFEPIME; CEFPIROME; CEPHALOSPORIN DERIVATIVE; MONOBACTAM DERIVATIVE; PENICILLIN G; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG HYDROLYSIS; ENTEROBACTERIACEAE; IN VITRO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PLASMID;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; PLASMIDS;

EID: 84863691469     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002; 46: 1-11.
2. Bush K, Jacoby GA. Updated functional classification of betalactamases. Antimicrob Agents Chemother 2010; 54: 969-76.
3. Mammeri H, Eb F, Berkani A, Nordmann P. Molecular characterization of AmpC, producing Escherichia coli clinical isolates recovered in a French hospital. J Antimicrob Chemother 2008; 61: 498-503.
4. Navarro F, Miro E, Mirelis B. Interpretive reading of enterobacteria antibiograms. Enferm Infecc Microbiol Clin 2010; 28: 638-45.
5. Nakano R, Okamoto R, Nakano Y, Kaneko K, Okitsu N, Hosaka Y, et al. CFE-1, a novel plasmid-encoded AmpC beta-lactamase with an ampR gene originating from Citrobacter freundii. Antimicrob Agents Chemother 2004; 48: 1151-1158.
6. Yu W, Bing L, Zhenhua L. AmpC promoter and attenuator mutations affect function of three Escherichia coli strains. Curr Microbiol 2009; 59: 244-247.
7. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009; 22: 161-182.
8. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010; 300: 371-379.
9. Jaurin B, Grundstrom T, Normark S. Sequence elements determining ampC promoter strength in E. coli. EMBO J 1982; 1: 875-881.
10. Olsson O, Bergstrom S, Lindberg FP, Normark S. AmpC beta-lactamase hyperproduction in Escherichia coli: natural ampicillin resistance generated by horizontal chromosomal DNA transfer from Shigella. Proc Natl Acad Sci U S A 1983; 80: 7556-7560.
11. Bobrowski MM, Matthew M, Barth PT, Datta N, Grinter NJ, Jacob AE, et al. Plasmid-determined beta-lactamase indistinguishable from the chromosomal beta-lactamase of Escherichia coli. J Bacteriol 1976; 125: 149-157.
12. Bauernfeind A, Chong Y, Schweighart S. Extended broad spectrum beta-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection 1989; 17: 316-321.
13. Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1990; 34: 2200-2209.
14. Luzzaro F, Brigante G, D'Andrea MM, Pini B, Giani T, Mantengoli E, et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents 2009; 33: 328-333.
15. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 2153-2162.
16. Haldorsen B, Aasnaes B, Dahl KH, Hanssen AM, Simonsen GS, Walsh TR, et al. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1- like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother 2008; 62: 694-702.
17. Empel J, Baraniak A, Literacka E, Mrowka A, Fiett J, Sadowy E, et al. Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 2008; 52: 2449-2454.
18. Hopkins KL, Batchelor MJ, Liebana E, Deheer-Graham AP, Threlfall EJ. Characterisation of CTX-M and AmpC genes in human isolates of Escherichia coli identified between 1995 and 2003 in England and Wales. Int J Antimicrob Agents 2006; 28: 180-192.
19. Pai H, Kang CI, Byeon JH, Lee KD, Park WB, Kim HB, et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 3720-3728.
20. Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ, Cavalieri SJ. Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community. Antimicrob Agents Chemother 2008; 52: 3814-3816.
21. Pitout JD, Gregson DB, Church DL, Laupland KB. Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg Infect Dis 2007; 13: 443-438.
22. Coudron PE, Hanson ND, Climo MW. Occurrence of extendedspectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases. J Clin Microbiol 2003; 41: 772-777.
23. Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC beta- lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol 2000; 38: 1791-1796.
24. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int J Antimicrob Agents 2006; 28: 578-581.
25. Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob Agents Chemother 2004; 48: 533-537.
26. Folster JP, Pecic G, Bolcen S, Theobald L, Hise K, Carattoli A, et al. Characterization of extended- spectrum cephalosporin- resistant Salmonella enterica serovar Heidelberg isolated from humans in the United States. Foodborne Pathog Dis 2010; 7: 181-187.
27. Mulvey MR, Bryce E, Boyd DA, Ofner-Agostini M, Land AM, Simor AE, et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 2005; 49: 358-365.
28. Baudry PJ, Mataseje L, Zhanel GG, Hoban DJ, Mulvey MR. Characterization of plasmids encoding CMY-2 AmpC beta-lactamases from Escherichia coli in Canadian intensive care units. Diagn Microbiol Infect Dis 2009; 65: 379-383.
29. Mataseje LF, Neumann N, Crago B, Baudry P, Zhanel GG, Louie M, et al. Characterization of cefoxitin-resistant Escherichia coli isolates from recreational beaches and private drinking water in Canada between 2004 and 2006. Antimicrob Agents Chemother 2009; 53: 3126-3130.
30. Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, et al. Prevalence and characterization of extended-spectrum beta-lactamase- and AmpC beta-lactamase- producing Escherichia coli: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011; 69: 326-334.
31. Rapoport M, Monzani V, Pasteran F, Morvay L, Faccone D, Petroni A, et al. CMY-2-type plasmid-mediated AmpC beta-lactamase finally emerging in Argentina. Int J Antimicrob Agents 2008; 31: 385-387.
32. Jure MA, Presti C, Cudmani NM, Grellet LM, Lopez C, Musa EH, et al. CMY-2-type plasmid-mediated AmpC betalactamases emerging in Tucuman, Argentina. Rev Argent Microbiol 2011; 43: 24-27.
33. Singtohin S, Chanawong A, Lulitanond A, Sribenjalux P, Auncharoen A, Kaewkes W, et al. CMY-2, CMY-8b, and DHA-1 plasmid- mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from a university hospital, Thailand. Diagn Microbiol Infect Dis 2010; 68: 271-277.
34. Yum JH, Kim S, Lee H, Yong D, Lee K, Cho SN, et al. Emergence and wide dissemination of CTX-M-type ESBLs, and CMY-2- and DHA-1-type AmpC beta-lactamases in Korean respiratory isolates of Klebsiella pneumoniae. J Korean Med Sci 2005; 20: 961-965.
35. Yan JJ, Hsueh PR, Lu JJ, Chang FY, Shyr JM, Wan JH, et al. Extended- spectrum beta-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan. Antimicrob Agents Chemother 2006; 50: 1861-1864.
36. Song W, Kim JS, Kim HS, Yong D, Jeong SH, Park MJ, et al. Increasing trend in the prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. Diagn Microbiol Infect Dis 2006; 55: 219-224.
37. Ding H, Yang Y, Lu Q, Wang Y, Chen Y, Deng L, et al. The prevalence of plasmid- mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children's hospitals in China. Eur J Clin Microbiol Infect Dis 2008; 27: 915-921.
38. Lee K, Lee M, Shin JH, Lee MH, Kang SH, Park AJ, et al. Prevalence of plasmid-mediated AmpC beta-lactamases in Escherichia coli and Klebsiella pneumoniae in Korea. Microb Drug Resist 2006; 12: 44-49.
39. Yamasaki K, Komatsu M, Abe N, Fukuda S, Miyamoto Y, Higuchi T, et al. Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the Kinki region of Japan. J Clin Microbiol 2010; 48: 3267-3273.
40. Yoo JS, Byeon J, Yang J, Yoo JI, Chung GT, Lee YS. High prevalence of extended- spectrum beta-lactamases and plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae isolated from long-term care facilities in Korea. Diagn Microbiol Infect Dis 2010; 67: 261-265.
41. Woodford N, Reddy S, Fagan EJ, Hill RL, Hopkins KL, Kaufmann ME, et al. Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. In the UK and Ireland. J Antimicrob Chemother 2007; 59: 102-105.
42. Roche C, Boo TW, Walsh F, Crowley B. Detection and molecular characterisation of plasmidic AmpC beta-lactamases in Klebsiella pneumoniae isolates from a tertiary-care hospital in Dublin, Ireland. Clin Microbiol Infect 2008; 14: 616-618.
43. Corvec S, Cremet L, Leprince C, Dauvergne S, Reynaud A, Lepelletier D, et al. Epidemiology of Escherichia coli clinical isolates producing AmpC plasmidic beta-lactamase during a 5-year period in a French teaching Hospital. Diagn Microbiol Infect Dis 2010; 67: 277-281.
44. Jorgensen RL, Nielsen JB, Friis-Moller A, Fjeldsoe-Nielsen H, Schonning K. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. J Antimicrob Chemother 2010; 65: 460-464.
45. Adler H, Fenner L, Walter P, Hohler D, Schultheiss E, Oezcan S, et al. Plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes: prevalence at a Swiss university hospital and occurrence of the different molecular types in Switzerland. J Antimicrob Chemother 2008; 61: 457-458.
46. Husickova V, Chroma M, Kolar M, Hricova K, Stosova T, Kantor L, et al. Analysis of ESBL- and AmpC-positive Enterobacteriaceae at the Department of Neonatology, University Hospital Olomouc. Curr Microbiol 2011; 62: 1664-1670.
47. Bou G, Oliver A, Ojeda M, Monzon C, Martinez-Beltran J. Molecular characterization of FOX-4, a new AmpC-type plasmid-mediated beta-lactamase from an Escherichia coli strain isolated in Spain. Antimicrob Agents Chemother 2000; 44: 2549-2553.
48. Navarro F, Perez-Trallero E, Marimon JM, Aliaga R, Gomariz M, Mirelis B. CMY-2- producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999-December 2000). J Antimicrob Chemother 2001; 48: 383-389.
49. Mata C, Miro E, Rivera A, Mirelis B, Coll P, Navarro F. Prevalence of acquired AmpC beta-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007. Clin Microbiol Infect 2010; 16: 472-476.
50. González-Sanz R, Herrera-Leon S, de la Fuente M, Arroyo M, Echeita MA. Emergence of extended-spectrum beta-lactamases and AmpC-type beta-lactamases in human Salmonella isolated in Spain from 2001 to 2005. J Antimicrob Chemother 2009; 64: 1181-1186.
51. Miró E, Agüero J, Bartolomé R, Fernández A, Conejo MC, Bou G, et al. Estudio de la prevalencia de betalactamasas AmpC plasmídicas y carbapenemasas en enterobacterias en España. En: XIV Congreso de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC); Barcelona; Enfemedades Infecciosas y Microbiología Clínica; 2010. Abstract 706.
52. Gude M, Seral C, Arias A, Cebollada R, González M, Salvo S, et al. Prevalencia de AmpC plasmídicas en enterobacterias de origin clínico. En: XIV Congreso de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC); 19-22 Mayo 2010; Barcelona; Enfermedades Infecciosas y Microbiología Clinica; 2010. Abstract 508.
53. Oteo J, Cercenado E, Cuevas O, Bautista V, Delgado-Iribarren A, Orden B, et al. AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis 2010; 67: 270-276.
54. Naseer U, Haldorsen B, Simonsen GS, Sundsfjord A. Sporadic occurrence of CMY-2- producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 2009; 16: 171-178.
55. Navarro F, Calvo J, Canton R, Fernandez-Cuenca F, Mirelis B. Detection of resistance phenotypes in gram-negative bacteria. Enferm Infecc Microbiol Clin 2011; 29: 524-534.
56. Robin F, Delmas J, Archambaud M, Schweitzer C, Chanal C, Bonnet R. CMT-type beta- lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection. Antimicrob Agents Chemother 2006; 50: 2403-2408.
57. Doi Y, Paterson DL. Detection of plasmid-mediated class C betalactamases. Int J Infect Dis 2007; 11: 191-197.
58. Martínez-Martínez L, Conejo MC, Pascual A, Hernández-Alles S, Ballesta S, Ramírez De Arellano-Ramos E, et al. Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles. Antimicrob Agents Chemother 2000; 44: 2534-2536.
59. Martínez-Martínez L, Hernández-Alles S, Alberti S, Tomas JM, Benedi VJ, Jacoby GA. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother 1996; 40: 342-348.
60. Conejo MC, Mata C, Navarro F, Pascual A. Detection and reporting beta-lactam resistance phenotypes in Escherichia coli and Klebsiella pneumoniae: a multicenter proficiency study in Spain. Diagn Microbiol Infect Dis 2008; 62: 317-325.
61. Black JA, Moland ES, Thomson KS. AmpC disk test for detection of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal AmpC beta-lactamases. J Clin Microbiol 2005; 43: 3110-3113.
62. Lee K, Hong SG, Park YJ, Lee HS, Song W, Jeong J, et al. Evaluation of phenotypic screening methods for detecting plasmidmediated AmpC beta-lactamases-producing isolates of Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2005; 53: 319-323.
63. Nasim K, Elsayed S, Pitout JD, Conly J, Church DL, Gregson DB. New method for laboratory detection of AmpC beta-lactamases in Escherichia coli and Klebsiella pneumoniae. J Clin Microbiol 2004; 42: 4799-4802.
64. Buynak JD, Vogeti L, Doppalapudi VR, Solomon GM, Chen H. Cephalosporin-derived inhibitors of beta-lactamase. Part 4: The C3 substituent. Bioorg Med Chem Lett 2002; 12: 1663-1666.
65. Richter HG, Angehrn P, Hubschwerlen C, Kania M, Page MG, Specklin JL, et al. Design, synthesis, and evaluation of 2 betaalkenyl penam sulfone acids as inhibitors of beta- lactamases. J Med Chem 1996; 39: 3712-3722.
66. Mirelis B, Rivera A, Miro E, Mesa RJ, Navarro F, Coll P. A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli. Enferm Infecc Microbiol Clin 2006; 24: 370-372.
67. Coudron PE. Inhibitor-based methods for detection of plasmidmediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J Clin Microbiol 2005; 43: 4163-4167.
68. Tenover FC, Emery SL, Spiegel CA, Bradford PA, Eells S, Endimiani A, et al. Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J Clin Microbiol 2009; 47: 294-299.
69. Yagi T, Wachino J, Kurokawa H, Suzuki S, Yamane K, Doi Y, et al. Practical methods using boronic acid compounds for identification of class C beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 2005; 43: 2551-2558.
70. Jeong SH, Song W, Park MJ, Kim JS, Kim HS, Bae IK, et al. Boronc acid disk tests for identification of extended-spectrum betalactamase production in clinical isolates of Enterobacteriaceae producing chromosomal AmpC beta-lactamases. Int J Antimicrob Agents 2008; 31: 467-471.
71. Pitout JD, Le PG, Moore KL, Church DL, Gregson DB. Detection of AmpC beta- lactamases in Escherichia coli, Klebsiella spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory. Clin Microbiol Infect 2010; 16: 165-170.
72. Tsakris A, Kristo I, Poulou A, Themeli-Digalaki K, Ikonomidis A, Petropoulou D, et al. Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory. J Clin Microbiol 2009; 47: 362-367.
73. Upadhyay S, Sen MR, Bhattacharjee A. Diagnostic utility of Boronic acid inhibition with different cephalosporins against Escherichia coli producing AmpC beta-lactamases. J Med Microbiol 2011; 87: 116-118.
74. Pournaras S, Poulou A, Tsakris A. Inhibitor-based methods for the detection of KPC carbapenemase-producing Enterobacteriaceae in clinical practice by using boronic acid compounds. J Antimicrob Chemother 2010; 65: 1319-1321.
75. Giske CG, Gezelius L, Samuelsen O, Warner M, Sundsfjord A, Woodford N. A sensitive and specific phenotypic assay for detection of metallo-beta-lactamases and KPC in Klebsiella pneumoniae withthe use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin Microbiol Infect 2010; 17: 552-556.
76. Lee W, Jung B, Hong SG, Song W, Jeong SH, Lee K, et al. Comparison of 3 phenotypic- detection methods for identifying plasmid- mediated AmpC beta-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis strains. Korean J Lab Med 2009; 29: 448-454.
77. Brolund A, Wisell KT, Edquist PJ, Elfstrom L, Walder M, Giske CG. Development of a real-time SYBRGreen PCR assay for rapid detection of acquired AmpC in Enterobacteriaceae. J Microbiol Methods 2010; 82: 229-233.
78. Hujer AM, Page MG, Helfand MS, Yeiser B, Bonomo RA. Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV betalactamases. J Clin Microbiol 2002; 40: 1947-1957.
79. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother 2010; 65 Suppl 3: iii25-33.
80. Sidjabat HE, Paterson DL, Qureshi ZA, Adams-Haduch JM, O'Keefe A, Pascual A, et al. Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clin Infect Dis 2009; 48: 739-744.
81. Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 2006; 44: 3318-3324.
82. Park YS, Yoo S, Seo MR, Kim JY, Cho YK, Pai H. Risk factors and clinical features of infections caused by plasmid-mediated AmpC beta-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2009; 34: 38-43.
83. Ofner-Agostini M, Simor A, Mulvey M, McGeer A, Hirji Z, Mc-Cracken M, et al. Risk factors for and outcomes associated with clinical isolates of Escherichia coli and Klebsiella species resistant to extended-spectrum cephalosporins among patients admitted to Canadian hospitals. Can J Infect Dis Med Microbiol 2009; 20: e43-e48.
84. Kang CI, Pai H, Kim SH, Kim HB, Kim EC, Oh MD, et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta- lactamase. J Antimicrob Chemother 2004; 54: 1130-1133.
85. Hernández JR, Conejo Mdel C, Pascual A. Comparative activity of ertapenem against extended-spectrum beta-lactamase-producing or plasmid-mediated AmpC beta-lactamase- producing Klebsiella pneumoniae. Enferm Infecc Microbiol Clin 2010; 28: 27-30.
86. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended- spectrum beta-lactamase- and AmpCproducing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005; 53: 257-264.
87. Cao VT, Arlet G, Ericsson BM, Tammelin A, Courvalin P, Lambert T. Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration. J Antimicrob Chemother 2000; 46: 895-900.
88. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta- lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-569.
89. Stapleton PD, Shannon KP, French GL. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein. Antimicrob Agents Chemother 1999; 43: 1206-1210.
90. Lee K, Yong D, Choi YS, Yum JH, Kim JM, Woodford N, et al. Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss. Int J Antimicrob Agents 2007; 29: 201-206.
91. Wang XD, Cai JC, Zhou HW, Zhang R, Chen GX. Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency. J Med Microbiol 2009; 58: 1196-1202.
92. Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and downregulation of the phosphate transport porin phoe. Antimicrob Agents Chemother 2006; 50: 3396-3406.
93. Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N. Activity of temocillin against prevalent ESBL- and AmpCproducing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006; 57: 1012-1014.
94. Glupczynski Y, Huang TD, Berhin C, Claeys G, Delmee M, Ide L, et al. In vitro activity of temocillin against prevalent extended- spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 2007; 26: 777-783.
95. Hope R, Warner M, Potz NA, Fagan EJ, James D, Livermore DM. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006; 58: 1312-1314.
96. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-R83.
97. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33: 1162-1167.
98. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28: 366-369.
99. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59: 786-790.
100. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535-543.
101. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem- resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16: 184-186.
102. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50.
103. Han C, Yang Y, Wang M, Wang A, Lu Q, Xu X, et al. The prevalence of plasmid-mediated quinolone resistance determinants among clinical isolates of ESBL or AmpC-producing Escherichia coli from Chinese pediatric patients. Microbiol Immunol 2010; 54: 123-128.